
LPCN
Lipocine
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
LPCN Profile
Lipocine Inc.
A biopharmaceutical company focused on developing therapeutics for central nervous system ("CNS") and metabolic disorders
675 Arapeen Drive
, Suite 202
, Salt Lake City
, Utah 84108
--
Lipocine Inc., incorporated in Delaware on June 19, 1997, is a specialized biopharmaceutical company dedicated to the application and development of its oral drug delivery technology in the biopharmaceutical field. Lipocine's proprietary drug delivery technology improves patient compliance and safety through oral regimens. The company's main development projects are for oral drug solutions with poor absorption effect. This type of drug has poor absorption effect and the dose is not enough to make the effect of the drug reach the circulatory system. The company has a series of patented product candidates with the following characteristics: good pharmacokinetic properties, conducive to meeting low dose requirements, bypassing initial metabolic processes, reducing side effects, and eliminating gastrointestinal interactions that limit drug activity. The company's product candidate, LPCN 1021, is a third-stage oral testosterone replacement therapy (TRT) with a dosage of twice a day, which is very convenient.